Medicus Pharma Ltd. (MDCX)
| Market Cap | 31.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.73M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,504 |
| Open | 3.000 |
| Previous Close | 2.750 |
| Day's Range | 2.670 - 3.000 |
| 52-Week Range | 1.800 - 3.230 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 10.00 (+269.0%) |
| Earnings Date | n/a |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada. [Read more]
Analyst Forecast
According to one analyst, the rating for MDCX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horse...
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile ...
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously ann...
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public...